Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries

 Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries

Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries

Shots:

  • Sandoz will hold IPR of Humira in certain countries and will also pay royalties to AbbVie. In response AbbVie will not make any payments to Sandoz
  • Humira’s license period for Sandoz in EU and the US will begin on 16 Oct, 2018 and 30 Sep, 2023 respectively
  • Hyrimoz (adalimumab, biosimilar) is Sandoz’s seventh biosimilar recently approved in EU including Norway, Iceland and Liechtenstein

Click here to read full press release/ article | Ref: Sandoz | Image: Spjnews

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post